GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Rayont Inc (OTCPK:RAYT) » Definitions » ROCE %

RAYT (Rayont) ROCE % : -12.19% (As of Mar. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Rayont ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Rayont's annualized ROCE % for the quarter that ended in Mar. 2023 was -12.19%.


Rayont ROCE % Historical Data

The historical data trend for Rayont's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rayont ROCE % Chart

Rayont Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Jun22
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -125.29 - -540.48 -38.48 16.21

Rayont Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.12 59.25 31.84 -11.28 -12.19

Rayont ROCE % Calculation

Rayont's annualized ROCE % for the fiscal year that ended in Jun. 2022 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2022 )  (A: Sep. 2020 )(A: Jun. 2022 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2022 )  (A: Sep. 2020 )(A: Jun. 2022 )
=0.885/( ( (4.814 - 4.219) + (14.193 - 3.867) )/ 2 )
=0.885/( (0.595+10.326)/ 2 )
=0.885/5.4605
=16.21 %

Rayont's ROCE % of for the quarter that ended in Mar. 2023 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2023 )  (Q: Dec. 2022 )(Q: Mar. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2023 )  (Q: Dec. 2022 )(Q: Mar. 2023 )
=-0.86/( ( (10.258 - 3.008) + (9.924 - 3.069) )/ 2 )
=-0.86/( ( 7.25 + 6.855 )/ 2 )
=-0.86/7.0525
=-12.19 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rayont  (OTCPK:RAYT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


Rayont ROCE % Related Terms

Thank you for viewing the detailed overview of Rayont's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Rayont Business Description

Traded in Other Exchanges
N/A
Address
228 Hamilton Avenue, 3rd Floor, Palo Alto, CA, USA, 94301
Rayont Inc is a clinical-stage life sciences company that holds the license for registering and commercializing Photosoft technology for the treatment of all cancers. This technology is an improved next-generation Photodynamic Therapy (PDT) that uses non-toxic photosensitizers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumors, and stimulates the immune system. It has been licensed in Australia, New Zealand, China, Malaysia, and Sub-Sahara Africa. It has generated revenue from digital learning solutions provided by Rayont Technologies.
Executives
Meng Leong Liew director 1313 N. GRAND AVE. #16, WALNUT CA 91789
Kha Foo Chin director, 10 percent owner, officer: President, Treasurer ROOM 1217 NORTH TOWER, CONORDIA PLAZA, NO 1 SCIENCE MUSEUM RD., TSIM SHA TSUI E, KOWLOON K3 NA